KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) Equity Ratio (2018 - 2025)

Castle Biosciences (CSTL) has disclosed Equity Ratio for 8 consecutive years, with 0.81 as the latest value for Q4 2025.

  • Quarterly Equity Ratio fell 5.15% to 0.81 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.81 through Dec 2025, down 5.15% year-over-year, with the annual reading at 0.81 for FY2025, 5.15% down from the prior year.
  • Equity Ratio hit 0.81 in Q4 2025 for Castle Biosciences, down from 0.83 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.96 in Q1 2021 to a low of 0.81 in Q4 2025.
  • Historically, Equity Ratio has averaged 0.89 across 5 years, with a median of 0.89 in 2021.
  • Biggest five-year swings in Equity Ratio: skyrocketed 30.9% in 2021 and later decreased 6.6% in 2022.
  • Year by year, Equity Ratio stood at 0.89 in 2021, then rose by 0.25% to 0.89 in 2022, then decreased by 3.27% to 0.86 in 2023, then decreased by 0.58% to 0.86 in 2024, then decreased by 5.15% to 0.81 in 2025.
  • Business Quant data shows Equity Ratio for CSTL at 0.81 in Q4 2025, 0.83 in Q3 2025, and 0.84 in Q2 2025.